Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.

@article{Emery2009LessRP,
  title={Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.},
  author={Paul Emery and Mark C Genovese and Ronald van Vollenhoven and John T. Sharp and Kaushik Patra and Eric H. Sasso},
  journal={The Journal of rheumatology},
  year={2009},
  volume={36 7},
  pages={1429-41}
}
OBJECTIVE To determine the relationship between radiographic progression and clinical response for adalimumab plus methotrexate (MTX) versus either monotherapy in patients with early rheumatoid arthritis (RA) in the PREMIER study. METHODS Patients with early RA who received adalimumab plus MTX (n = 240), adalimumab (n = 222), or MTX (n = 216) were grouped by American College of Rheumatology (ACR) response, 28-joint Disease Activity Score (DAS28), or remission-like state [tender joint count… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 37 references

Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis

  • MC Genovese, R vanVollenhoven, JT Sharp, K Patra, EH Sasso
  • J Rheumatol
  • 2009

Modified disease activity scores that 1440

  • Prevoo MLL, HH Kuper, MA vanLeeuwen, van de Putte LBA, van Riel LBA
  • The Journal of Rheumatology
  • 2009

Similar Papers

Loading similar papers…